Robinson Chandler (CIK 1727334) reported 19 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-07-02). Recent activity: Sell MNPR (4,084 shares), Buy MNPR (12,873 shares), Sell MNPR (1,972 shares), Buy MNPR (6,732 shares), Buy MNPR (62,815 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Sell | 4,084 | $378,138 |
| 2026-07-02 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Buy | 12,873 | $0 |
| 2026-04-02 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Sell | 1,972 | $108,046 |
| 2026-04-02 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Buy | 6,732 | $0 |
| 2026-01-30 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Buy | 62,815 | $0 |
| 2026-01-05 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Buy | 8,724 | $0 |
| 2026-01-05 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Sell | 2,558 | $167,037 |
| 2025-10-02 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Buy | 8,726 | $0 |
| 2025-10-02 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Sell | 2,646 | $216,099 |
| 2025-09-26 | Monopar Therapeutics (MNPR) | Insider | Sell | 550,229 | $35.0M |
| 2025-07-16 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Buy | 16,800 | $168 |
| 2025-07-16 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Sell | 16,800 | $672,000 |
| 2025-07-02 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Buy | 13,344 | $0 |
| 2025-07-02 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Sell | 5,865 | $209,850 |
| 2025-04-04 | Monopar Therapeutics (MNPR) | Insider | Sell | 33,334 | $1.2M |
| 2025-04-02 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Buy | 4,106 | $0 |
| 2025-04-02 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Sell | 1,204 | $43,838 |
| 2025-03-07 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Buy | 6,002 | $0 |
| 2025-03-07 | Monopar Therapeutics (MNPR) | Chief Executive Officer | Sell | 1,759 | $55,760 |
Source: SEC Form 4 filings · as of 2026-07-02